Consequently, given the impossibility to hit a mutated allele, Cas9 and sgRNAs need to be selectively delivered to cancer cells to prevent the possible detrimental consequences of FOSL1 knockout in non-neoplastic cells. This evidence concerns the gene FOSL1 and cancer.